Mozart Therapeutics
Seattle
About Mozart Therapeutics
Mozart Therapeutics is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is using a novel regulatory CD8 T cell network to create disease-modifying CD8 Treg modulators for a variety of autoimmune diseases. Mozart is developing a pipeline of first-in-class 'CD8 Treg modulators with the goal of restoring long-term immune balance and preventing the progressive damage caused by an autoreactive and pathogenic immune response.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $80.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2023)
- Website: mozart-tx.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/mozart-therapeutics-107484 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.